Stock 301230 PHARMARESOURCES (SHANGHAI) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PharmaResources (Shanghai) Co., Ltd.

Equities

301230

CNE1000065Q9

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 07/06/2024 am IST 		5-day change 1st Jan Change
29.93 CNY +1.22% Intraday chart for PharmaResources (Shanghai) Co., Ltd. -8.94% -16.40%
25/04 PharmaResources Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
23/04 PharmaResources Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 4,107 3,853 3,202 -
Enterprise Value (EV) 1 4,107 3,853 3,202 3,202
P/E ratio 48.6 x 102 x 22.2 x 16.5 x
Yield - - - -
Capitalization / Revenue 8.58 x 7.87 x 3.76 x 2.86 x
EV / Revenue 8.58 x 7.87 x 3.76 x 2.86 x
EV / EBITDA 41.7 x 54.1 x 18.4 x 13.5 x
EV / FCF - - - -
FCF Yield - - - -
Price to Book 3.69 x 3.45 x 2.47 x 2.19 x
Nbr of stocks (in thousands) 1,07,623 1,07,623 1,06,993 -
Reference price 2 38.16 35.80 29.93 29.93
Announcement Date 21/04/23 23/04/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 478.9 489.7 852 1,119
EBITDA 1 - 98.45 71.21 174 238
EBIT 1 - 72.85 37.44 165 221
Operating Margin - 15.21% 7.65% 19.37% 19.75%
Earnings before Tax (EBT) 1 - 72.92 36.76 165 221
Net income 1 73.58 67.18 37.62 146 195
Net margin - 14.03% 7.68% 17.14% 17.43%
EPS 2 0.9143 0.7857 0.3500 1.350 1.810
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 14/04/22 21/04/23 23/04/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1
Net sales 1 130.7
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 3.668
Net margin 2.81%
EPS -
Dividend per Share -
Announcement Date 25/04/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 13.4% 3.39% 11.2% 13.2%
ROA (Net income/ Total Assets) - - - 9.3% 11.1%
Assets 1 - - - 1,570 1,757
Book Value Per Share 2 - 10.30 10.40 12.10 13.70
Cash Flow per Share - - - - -
Capex 1 - 124 248 90 90
Capex / Sales - 25.89% 50.69% 10.56% 8.04%
Announcement Date 14/04/22 21/04/23 23/04/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for PharmaResources (Shanghai) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
29.93
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHARMARESOURCES (SHANGHAI) CO., LTD. Stock PharmaResources (Shanghai) Co., Ltd.
-16.40% 44Cr
MODERNA, INC. Stock Moderna, Inc.
+51.85% 5.79TCr
LONZA GROUP AG Stock Lonza Group AG
+41.42% 4.03TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 3.99TCr
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 2.85TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 2.64TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 1.93TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 1.24TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 1.22TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 1.22TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 301230 Stock
  4. Financials PharmaResources (Shanghai) Co., Ltd.